Of nearly 1 million individuals screened for COVID-19 symptoms or exposure at entrances of a U.S. academic medical center from March 17, 2020, to May 8, 2021, fewer than 0.1% had a failed screening. The estimated cost to identify one screening failure was $2,351.
A systematic review and meta-analysis of studies addressing perioperative management of antithrombotic therapy, developed for a clinical practice guideline by the American College of Chest Physicians, found that data were sparse overall.
One recent study compared the predictive value of the HAS-BLED, ATRIA, and ORBIT scores in patients with cancer and afib, while another looked at clot, bleeding, and mortality risk with warfarin versus a direct-acting oral anticoagulant in patients with both conditions.
A post hoc analysis of an industry-funded trial found that dapagliflozin reduced overall risk of hospitalization as well as risk of hospitalization ending in death in patients with chronic kidney disease (CKD).